Topics
Glioblastoma | Treatment | Glucocorticoids
Home > Publications > Topics > Glioblastoma > Treatment > Glucocorticoids
*Rangwala BS, Shakil A, Mustafa MS, Rangwala HS, Fatima H, Siddiq
MA.
Losartan
and Immune Checkpoint Inhibitors in
Glioblastoma: An Appropriate Substitute for
Steroids.
Ann
Neurosci. 2023 Nov 3;31(3):152-154. doi:
10.1177/09727531231191880. PMID:
39156623. Perspective. ˍ
Arora H, Mammi M, Patel NM, Zyfi D,
Dasari HR, Yunusa I, Simjian T, Smith TR, Mekary RA.
Dexamethasone
and overall survival and progression free survival in patients
with newly diagnosed glioblastoma: a meta-analysis.
J
Neurooncol. 2023
Dec 27. doi:
10.1007/s11060-023-04549-3. PMID:
38151699. Meta-analysis˰ ˍ
*Scheffler P, Fung C, Momjian S, Koessinger D, Häni L,
Neidert N, Straehle J, Volz F, Schnell O, Beck J, El Rahal
A.
Dexamethasone in Patients with
Glioblastoma: A Systematic Review and Meta-Analysis.
Cancers
(Basel). 2024 Apr 1;16(7):1393. doi:
10.3390/cancers16071393. PMID:
38611071. Review; Meta-analysis. ˍ
Keul J, Sperling S, Rohde V, Mielke D, Ninkovic M.
Riluzole
Reverses a Number of Undesirable Effects of Dexamethasone in
Glioblastoma Cells.
Anticancer
Res. 2024 Apr 27;44(5):1829-1835. doi:
10.21873/anticanres.16984. PMID:
38677733. Laboratory investigation. ˍ
*Gonzalez-Aponte MF, Damato AR, Simon T, Aripova N, Darby F, Rubin
JB, Herzog ED.
Daily glucocorticoids
promote glioblastoma growth and circadian synchrony to the
host.
bioRxiv
[Preprint]. 2024 May 6:2024.05.03.592418. doi:
10.1101/2024.05.03.592418. PMID:
38766060. Laboratory investigation. ˍ
*Romano A, De Giorgi S, Romano A, Moltoni G, Ascolese AM,
Stoppacciaro A, Bozzao A.
"Vanishing"
glioblastoma: A case report and review of the literature.
Radiol
Case Rep. 2024 May 18;19(8):3276-3282. doi:
10.1016/j.radcr.2024.04.040. PMID:
38812592. Case report; Review. ˍ